Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

information)(Unaudited)Three Months EndedNine Months EndedSeptember 30, September 30,2010200920102009Revenue:Product sales and royalties

$  7,230$
7,461$  21,968$  24,456License, collaboration and other

30,6952,76291,7578,466Total revenue

37,92510,223113,72532,922Operating costs and expenses:Cost of goods sold

6,2456,13415,43022,139Research and development

27,72423,03176,61070,396General and administrative

10,1819,91729,40130,024Total operating costs and expenses

44,15039,082121,441122,559Income (loss) from operations

(6,225)(28,859)(7,716)(89,637)Non-operating income (expense):Interest income

3695601,2253,160Interest expense

(2,826)(2,928)(8,686)(9,213)Other income, net

249120436368Total non-operating expense

(2,208)(2,248)(7,025)(5,685)Loss before provision (benefit) for income taxes

(8,433)(31,107)(14,741)(95,322)Provision (Benefit) for income taxes

278(140)617(479)Net loss

$ (8,711)$ (30,967)$ (15,358)$ (94,843)Basic and diluted net loss per share

$   (0.09)$
(0.33)$
(0.16)$
(1.02)Weighted average shares outstanding used incomputing basic and diluted net loss pershare

94,21392,78993,97292,621NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months Ended Sept 30,20102009Cash flows from operating activities:Net loss

$ (15,358)$   (94,843)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

12,49911,076Stock-based compensation

12,7167,290Deferred rent

1,084-Other non-cash transactions

(1,260)(124)Changes in operating assets and liabilities:Accounts receivable

(752)4,505Inventory

(4,989)389Other assets

1(1,272)Accounts payable

1,755(4,047)Accrued compensation

500(1,859)Accrued expenses

4,090(4,610)Accrued clinical trial expenses


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 20, 2015 ... has announced the addition of the "Cardiometabolic ... Afrezza,s discounted pricing is in line ... is critical to the product,s commercial appeal. However, ... prevent Afrezza from gaining a sizeable share of ...
(Date:7/27/2015)... WASHINGTON , July 27, 2015 Even ... Larkin , MD, FACP, NCMP, as scientific co-chair for ... health coalition to serve as an expert voice in ... treatment options for women struggling with Hypoactive Sexual Desire ... "I am honored to join Even ...
(Date:7/27/2015)... , July 20, 2015 Research and ... of the "D-dimer Testing Market - Global ... Forecast 2014 - 2022" report to their ... vitro diagnostics market is one of the fastest ... attributed to the improved health care awareness, preference ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 2Dr. Lisa Larkin Joins the Even the Score Coalition as Scientific Co-Chair 3D-dimer Testing Market - Global Industry Analysis 2015 2D-dimer Testing Market - Global Industry Analysis 2015 3
... (Nasdaq: VOLC ) today announced its intention to ... principal amount of convertible senior notes due September 1, 2015 ... as amended (the "Securities Act"). Prior to June 1, 2015, ... conversion, holders will receive up to the principal amount of ...
... Inc. (Nasdaq: ANDS ) announced today that it ... Friday, September 17, 2010 at 8:35 a.m. EDT (5:35 a.m. ... in Boston.  Steve Worland, Ph.D., President and Chief Executive Officer ... clinical development programs. Dr. Worland will also present ...
Cached Medicine Technology:Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 2Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 3Volcano Corporation to Offer $100 Million Convertible Senior Notes Due 2015 4Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences 2
(Date:7/28/2015)... , ... July 28, 2015 , ... Want to improve ... – or in your easy chair? Luckily, there are plenty of back-friendly cardio exercises ... an orthopedic spine surgeon at Atlantic Spine Center . , It’s simply ...
(Date:7/27/2015)... , ... July 28, 2015 , ... Almost a year ... to offer behavioral health counseling for persons who are obese and those who are ... less clear. , That mandate will affect any commercial health plan with a program ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... The ... 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She is recognized ... over 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for ...
(Date:7/27/2015)... , ... July 27, 2015 , ... The heroin epidemic ... reported WCNC on July 7th. The rate for heroin usage has continued ... gone down considerably, and is a less expensive alternative for those with an addiction ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Looking to ... smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental webpage ... take care of their teeth. , “Horizon is committed to offering our 3.8 ...
Breaking Medicine News(10 mins):Health News:Safe Cardio for Back Pain Sufferers 2Health News:Safe Cardio for Back Pain Sufferers 3Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... reimburses patients and physicians who have been shortchanged ... American Medical Association (AMA), along with the Medical Society ... State Medical Association, claims victory with the settlement agreement ... The $350 million settlement marks the largest monetary settlement ...
... Philadelphia Attorney Stephen Sheller,s Whistleblower Clients Help ... Criminal Fine in Eli Lilly & Company ... 2003 Representing Six Whistleblowers PHILADELPHIA, Jan. 15 ... ("Lilly") will pay federal and state governments ...
... Eli Lilly and Company announced today it has ... pay more than 1.4 billion in criminal and civil ... multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, ... with its market practices for its blockbuster atypical antipsychotic, ...
... transplanted because of the generosity of donors and their familiesPHILADELPHIA, ... kid on the football field, but he spent his life ... graduated high school. For a 16-year-old from Hazleton, Pa. ... certainly unique. But as his father Paul Sr. talked ...
... $515 Million Criminal Fine is Largest Individual Corporate Criminal ... 15 American pharmaceutical giant Eli Lilly and Company ... for promoting its drug Zyprexa for uses not approved ... of Justice announced today. This resolution includes ...
... CINCINNATI, Jan. 15, 2009 The Procter & Gamble,Company ... organizational changes: , -- Mariano ... June 30, 2009, after 33 years of service. He ... 2009, when he will focus on working,closely with his ...
Cached Medicine News:Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 2Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 3Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 4Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 2Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 3Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 4Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 2Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 3Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Procter & Gamble Announces Organizational Changes 2